Allogene Therapeutics (ALLO) Short Interest Ratio & Short Volume

$2.70

+0.09 (+3.45%)

(As of 10/4/2024 ET)

Allogene Therapeutics Short Interest Data

Allogene Therapeutics (ALLO) has a short interest of 39.19 million shares, representing 28.70% of the float (the number of shares available for trading by the public). This marks a 0.64% increase in short interest from the previous month. The short interest ratio (days to cover) is 17.0, indicating that it would take 17.0 days of the average trading volume of 2.52 million shares to cover all short positions.

Current Short Interest: 39,190,000 shares
Previous Short Interest: 38,940,000 shares
Change Vs. Previous Month: +0.64%
Dollar Volume Sold Short: $116.00 million
Short Interest Ratio: 17.0 Days to Cover
Last Record Date: September 15, 2024

Outstanding Shares: 209,000,000 shares
Float Size: 136,570,000 shares
Short Percent of Float: 28.70%
Today's Trading Volume: 1,383,041 shares
Average Trading Volume: 2,518,994 shares
Today's Volume Vs. Average: 55%

Short Selling Allogene Therapeutics?

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Allogene Therapeutics and its competitors with MarketBeat's FREE newsletter.

Short Interest Chart Days to Cover Chart Short Percent of Float Chart

ALLO Short Interest Over Time

ALLO Days to Cover Over Time

ALLO Percentage of Float Shorted Over Time

Ad Weiss Ratings

Who are Nvidia’s New Silent Partners?

Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.

I call these Nvidia’s “Silent Partners.”

Allogene Therapeutics Short Interest History

Export to Excel

Report Date	Total Shares Sold Short	Dollar Volume Sold Short	Change from Previous Report	Percentage of Float Shorted	Days to Cover	Price on Report Date
9/15/2024	39,190,000 shares	$116.00 million	+0.6%	28.7%	17	$2.96
8/31/2024	38,940,000 shares	$102.41 million	-0.7%	28.5%	15.8	$2.63
8/15/2024	39,230,000 shares	$90.23 million	+3.9%	28.7%	14.5	$2.30
7/31/2024	37,750,000 shares	$110.99 million	-12.7%	27.6%	12.9	$2.94
7/15/2024	43,230,000 shares	$128.83 million	+4.5%	31.6%	14.7	$2.98
6/30/2024	41,380,000 shares	$96.42 million	-4.4%	30.3%	15.3	$2.33
Get the Latest News and Ratings for ALLO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
6/15/2024	43,280,000 shares	$101.71 million	+6.7%	31.7%	17.1	$2.35
5/31/2024	40,570,000 shares	$101.43 million	+11.4%	33.5%	16.2	$2.50
5/15/2024	36,430,000 shares	$108.56 million	+7.6%	30.1%	15.7	$2.98
4/30/2024	33,870,000 shares	$93.48 million	+8.0%	32.0%	15.5	$2.76
4/15/2024	31,360,000 shares	$111.33 million	+2.4%	30.0%	13.9	$3.55
3/31/2024	30,620,000 shares	$136.87 million	+10.3%	29.3%	11.7	$4.47
3/15/2024	27,750,000 shares	$129.32 million	+11.0%	26.6%	10	$4.66
2/29/2024	25,010,000 shares	$122.80 million	+6.7%	24.1%	8.3	$4.91
2/15/2024	23,450,000 shares	$116.31 million	+1.6%	22.6%	7.7	$4.96
1/31/2024	23,090,000 shares	$81.28 million	-23.6%	22.2%	7.4	$3.52
1/15/2024	30,210,000 shares	$97.28 million	-3.5%	28.5%	10.3	$3.22
12/31/2023	31,320,000 shares	$100.54 million	-6.7%	29.6%	11.9	$3.21
12/15/2023	33,550,000 shares	$90.92 million	+5.3%	31.7%	14.3	$2.71
11/30/2023	31,860,000 shares	$74.87 million	-1.5%	30.1%	16.8	$2.35
11/15/2023	32,340,000 shares	$87.96 million	-5.0%	30.6%	18.9	$2.72
10/31/2023	34,030,000 shares	$95.96 million	+10.7%	32.2%	22	$2.82
10/15/2023	30,730,000 shares	$98.03 million	-10.0%	29.2%	18	$3.19
9/30/2023	34,130,000 shares	$108.19 million	+2.1%	32.2%	19	$3.17
9/15/2023	33,420,000 shares	$130.00 million	+4.1%	31.5%	16.2	$3.89
8/31/2023	32,110,000 shares	$124.91 million	-2.0%	30.3%	12.4	$3.89
8/15/2023	32,770,000 shares	$133.70 million	-13.6%	30.9%	12.5	$4.08
7/31/2023	37,910,000 shares	$188.03 million	-8.1%	39.4%	14.3	$4.96
7/15/2023	41,260,000 shares	$204.65 million	+8.1%	53.9%	15.3	$4.96
6/30/2023	38,180,000 shares	$189.75 million	+1.7%	49.9%	14.1	$4.97
6/15/2023	37,560,000 shares	$186.67 million	-6.2%	49.1%	15.1	$4.97
5/31/2023	40,030,000 shares	$210.16 million	-1.4%	52.1%	20.4	$5.25
5/15/2023	40,590,000 shares	$273.58 million	-0.2%	52.8%	19.6	$6.74
4/30/2023	40,650,000 shares	$220.73 million	-1.4%	53.3%	20.3	$5.43
4/15/2023	41,220,000 shares	$205.69 million	+0.5%	54.5%	22.2	$4.99
3/31/2023	41,010,000 shares	$202.59 million	+3.0%	54.3%	22.5	$4.94
3/15/2023	39,800,000 shares	$225.27 million	+8.0%	49.6%	20.9	$5.66
2/28/2023	36,860,000 shares	$234.06 million	+4.9%	46.0%	19.4	$6.35
2/15/2023	35,140,000 shares	$254.06 million	+2.1%	44.0%	18.4	$7.23
1/31/2023	34,410,000 shares	$265.65 million	+0.7%	43.1%	18	$7.72
Next opportunity for crypto millions (Ad) The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust.
1/15/2023	34,160,000 shares	$241.17 million	+2.2%	42.7%	18.1	$7.06
12/30/2022	33,430,000 shares	$210.27 million	+9.5%	41.8%	18	$6.29
12/15/2022	30,530,000 shares	$216.15 million	+0.2%	38.2%	16	$7.08
11/30/2022	30,470,000 shares	$300.43 million	-3.2%	38.1%	16.5	$9.86
11/15/2022	31,460,000 shares	$311.45 million	+1.6%	39.3%	18.2	$9.90
10/31/2022	30,960,000 shares	$318.89 million	+3.0%	39.3%	18.3	$10.30
10/15/2022	30,050,000 shares	$305.91 million	+8.9%	38.3%	18	$10.18
9/30/2022	27,590,000 shares	$297.97 million	+24.2%	35.2%	16	$10.80
9/15/2022	22,220,000 shares	$311.08 million	+0.9%	28.3%	12.8	$14.00
8/31/2022	22,020,000 shares	$301.89 million	-2.4%	28.1%	12	$13.71
8/15/2022	22,570,000 shares	$390.01 million	+0.8%	28.8%	11.6	$17.28
7/31/2022	22,400,000 shares	$290.75 million	-0.1%	28.6%	10.9	$12.98
7/15/2022	22,430,000 shares	$287.33 million	-0.3%	28.6%	10.2	$12.81
6/30/2022	22,490,000 shares	$256.39 million	+2.0%	28.5%	10.5	$11.40
6/15/2022	22,060,000 shares	$212.22 million	+9.5%	28.0%	10.8	$9.62
5/31/2022	20,150,000 shares	$159.79 million	+13.9%	25.7%	10.8	$7.93
5/15/2022	17,690,000 shares	$127.90 million	-0.4%	22.5%	9.6	$7.23
4/30/2022	17,760,000 shares	$148.30 million	-1.7%	24.3%	10.4	$8.35
4/15/2022	18,060,000 shares	$149.00 million	+18.6%	24.8%	11.4	$8.25
3/31/2022	15,230,000 shares	$138.75 million	+4.8%	16.1%	8.9	$9.11
3/15/2022	14,540,000 shares	$113.41 million	+18.7%	19.8%	8.6	$7.80
2/28/2022	12,250,000 shares	$112.09 million	+16.9%	16.7%	7.5	$9.15
2/15/2022	10,480,000 shares	$106.79 million	+10.0%	14.3%	6.8	$10.19
1/31/2022	9,530,000 shares	$109.12 million	+5.1%	14.3%	6.6	$11.45
1/15/2022	9,070,000 shares	$120.45 million	+19.7%	13.6%	6.2	$13.28
12/31/2021	7,580,000 shares	$113.09 million	+34.9%	11.4%	4.1	$14.92
12/15/2021	5,620,000 shares	$86.38 million	+4.7%	8.4%	2.7	$15.37
11/30/2021	5,370,000 shares	$99.29 million	-5.3%	8.1%	2.9	$18.49
11/15/2021	5,670,000 shares	$106.99 million	+19.6%	8.5%	3.1	$18.87
10/29/2021	4,740,000 shares	$81.72 million	+0.2%	7.1%	2.6	$17.24
10/15/2021	4,730,000 shares	$77.95 million	-40.7%	7.1%	2.8	$16.48
9/30/2021	7,980,000 shares	$205.09 million	+1.7%	12.0%	6.7	$25.70
9/15/2021	7,850,000 shares	$196.25 million	-6.0%	11.8%	9.5	$25.00
8/31/2021	8,350,000 shares	$199.15 million	-0.4%	11.7%	9.4	$23.85
8/13/2021	8,380,000 shares	$179.67 million	-9.6%	11.7%	7.5	$21.44
7/30/2021	9,270,000 shares	$203.48 million	-2.2%	13.0%	7.1	$21.95
7/15/2021	9,480,000 shares	$211.88 million	+0.2%	13.3%	7.1	$22.35
6/30/2021	9,460,000 shares	$246.72 million	+15.5%	13.3%	7	$26.08
6/15/2021	8,190,000 shares	$205.00 million	+3.0%	11.5%	7	$25.03
5/28/2021	7,950,000 shares	$204.32 million	-3.4%	11.3%	6.8	$25.70
5/14/2021	8,230,000 shares	$221.72 million	+13.5%	11.6%	7.8	$26.94
4/30/2021	7,250,000 shares	$231.86 million	-12.7%	10.2%	8.5	$31.98
4/15/2021	8,300,000 shares	$266.85 million	-3.8%	11.9%	10.1	$32.15
3/31/2021	8,630,000 shares	$288.50 million	-16.1%	12.4%	10	$33.43
3/15/2021	10,290,000 shares	$395.96 million	-10.9%	14.6%	11.1	$38.48
2/26/2021	11,550,000 shares	$378.72 million	+4.2%	16.5%	12.4	$32.79
2/12/2021	11,080,000 shares	$381.15 million	-4.0%	15.8%	12.6	$34.40
1/29/2021	11,540,000 shares	$398.25 million	-15.9%	16.8%	12.8	$34.51
1/15/2021	13,720,000 shares	$426.28 million	+5.2%	20.1%	14.8	$31.07
12/31/2020	13,040,000 shares	$347.39 million	+15.7%	19.1%	15.4	$26.64
Next opportunity for crypto millions (Ad) The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust.
12/15/2020	11,270,000 shares	$315.56 million	+5.8%	16.5%	13.8	$28.00
11/30/2020	10,650,000 shares	$335.69 million	+0.7%	15.7%	14.1	$31.52
11/15/2020	10,580,000 shares	$339.30 million	+5.1%	15.6%	15.4	$32.07
10/30/2020	10,070,000 shares	$358.19 million	-0.5%	14.9%	15.5	$35.57
10/15/2020	10,120,000 shares	$436.88 million	-2.3%	15.0%	17.2	$43.17
9/30/2020	10,360,000 shares	$390.68 million	+1.5%	15.4%	17.7	$37.71
9/15/2020	10,210,000 shares	$363.58 million	-5.0%	15.1%	16.3	$35.61
8/31/2020	10,750,000 shares	$383.24 million	+0.6%	15.9%	16.6	$35.65
8/14/2020	10,690,000 shares	$394.78 million	-2.8%	15.9%	11.9	$36.93
7/31/2020	11,000,000 shares	$403.37 million	-8.8%	16.7%	9.6	$36.67
7/15/2020	12,060,000 shares	$501.58 million	-10.1%	18.4%	10.1	$41.59
6/30/2020	13,420,000 shares	$561.76 million	+16.8%	23.3%	10.9	$41.86
6/15/2020	11,490,000 shares	$482.69 million	-13.3%	20.2%	9.5	$42.01
5/29/2020	13,250,000 shares	$638.12 million	-1.6%	23.6%	10.9	$48.16
5/15/2020	13,460,000 shares	$604.49 million	+2.2%	26.5%	12.9	$44.91
4/30/2020	13,170,000 shares	$380.61 million	-6.7%	26.0%	17.4	$28.90
4/15/2020	14,110,000 shares	$362.20 million	+6.9%	27.5%	19.9	$25.67
3/31/2020	13,200,000 shares	$390.72 million	-0.3%	26.1%	19.8	$29.60
3/13/2020	13,240,100 shares	$300.42 million	+2.2%	40.9%	16.7	$22.69
2/28/2020	12,950,000 shares	$246.18 million	-0.5%	40.0%	19.8	$19.01
2/14/2020	13,010,000 shares	$338.00 million	+1.3%	26.6%	20.3	$25.98
1/31/2020	12,850,000 shares	$327.03 million	-1.4%	26.3%	21.1	$25.45
1/15/2020	13,030,000 shares	$305.16 million	+1.6%	26.6%	22.2	$23.42
12/31/2019	12,830,000 shares	$300.35 million	+9.6%	26.2%	23.8	$23.41

ALLO Short Interest - Frequently Asked Questions

What is Allogene Therapeutics' current short interest?: Short interest is the volume of Allogene Therapeutics shares that have been sold short but have not yet been closed out or covered. As of September 15th, investors have sold 39,190,000 shares of ALLO short. 28.70% of Allogene Therapeutics' shares are currently sold short. Learn More on Allogene Therapeutics' current short interest.
What is a good short interest ratio for Allogene Therapeutics?: The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALLO shares currently have a short interest ratio of 17.0. Learn More on Allogene Therapeutics's short interest ratio.
Which institutional investors are shorting Allogene Therapeutics?: As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Allogene Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.
What is a good short interest percentage for Allogene Therapeutics?: Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 28.70% of Allogene Therapeutics' floating shares are currently sold short.
Is Allogene Therapeutics' short interest increasing or decreasing?: Allogene Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 39,190,000 shares, an increase of 0.6% from the previous total of 38,940,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.
What is Allogene Therapeutics' float size?: Allogene Therapeutics currently has issued a total of 209,000,000 shares. Some of Allogene Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Allogene Therapeutics currently has a public float of 136,570,000 shares.

How does Allogene Therapeutics' short interest compare to its competitors?: 28.70% of Allogene Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Allogene Therapeutics: bluebird bio, Inc. (44.27%), Neumora Therapeutics, Inc. (17.34%), Beam Therapeutics Inc. (13.32%), Recursion Pharmaceuticals, Inc. (26.54%), Vericel Co. (7.32%), Novavax, Inc. (23.88%), Immunocore Holdings plc (17.39%), BioCryst Pharmaceuticals, Inc. (11.78%), Tectonic Therapeutic (0.72%), Tarsus Pharmaceuticals, Inc. (24.95%),
Which stocks are the most shorted right now?: As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($6.15 billion), Charter Communications, Inc. ($4.04 billion), Paychex, Inc. ($2.77 billion), Nu Holdings Ltd. ($2.71 billion), Cencora, Inc. ($2.34 billion), Aptiv PLC ($2.18 billion), Tractor Supply ($2.07 billion), International Paper ($2.01 billion), AppLovin Co. ($1.95 billion), and Moderna, Inc. ($1.89 billion). View all of the most shorted stocks.
What does it mean to sell short Allogene Therapeutics stock?: Short selling ALLO is an investing strategy that aims to generate trading profit from Allogene Therapeutics as its price is falling. ALLO shares are trading up $0.09 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.
How does a short squeeze work against Allogene Therapeutics?: A short squeeze for Allogene Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALLO, which in turn drives the price of the stock up even further.
How often is Allogene Therapeutics' short interest reported?: Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALLO, twice per month. The most recent reporting period available is September, 15 2024.